Mastalgia refractory to drug treatment

C. Gateley, P.R. Maddox, R E Mansel, L E Hughes
In: Journal of British Surgery · 1990 · vol. 77(10) , pp. 1110–1112 · doi:10.1002/bjs.1800771011 · PMID:2224458 · W2057302113
article OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This study investigated treatment outcomes for 126 mastalgia patients refractory to first-line therapy, finding varied response rates for cyclical and non-cyclical mastalgia across subsequent treatments, with danazol showing sustained efficacy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Management of the patient with mastalgia who fails to respond to first line therapy is a difficult problem and there is a group of patients who do not respond to any therapy. A group of 126 patients with mastalgia who failed to respond to first line therapy and completed further treatment options was studied. The response rate of those with cyclical mastalgia fell to 57 and 25 per cent for second and third line therapy respectively. Equivalent figures for non-cyclical mastalgia were 24 and 21 per cent. Danazol maintains a high response rate after the failure of other drugs, whereas the second line response to bromocriptine and evening primrose oil is poor. Unresponsive patients were matched to a group of patients who responded to first line therapy, and reproductive and historical factors were compared using the chi 2 test, but failed to identify which patients would respond to therapy.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

Cited by (4)

References (18)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-10T11:25:12.659626+00:00
License: CC0 · commercial use OK